|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
1 Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
2 Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas, 75390-9057, United States
* To whom correspondence should be addressed. E-mail: jerry.niederkorn{at}utsouthwestern.edu.
| Abstract |
|---|
Purpose: To assess the expression of PD-L1 on human uveal melanomas and its potential to suppress T cell function.
Methods: A panel of primary and metastatic uveal melanoma cell lines was evaluated for PD-L1 expression by RT-PCR and flow cytometric analysis. Uveal melanoma-containing eyes were examined for PD-L1 expression by immunohistochemistry. PD-L1 function was tested by coculturing IFN-
-pretreated uveal melanoma cells with activated Jurkat T cells for 48 hours and assessing T cell production of IL-2 by ELISA.
Results: Five of the nine primary and one of the five metastatic uveal melanoma cell lines tested constitutively expressed PD-L1 protein at various levels. However, all primary and metastatic uveal melanoma cell lines upregulated PD-L1 expression after stimulation with IFN-
. Immunhistochemistry demonstrated that PD-L1 was not expressed by uveal melanomas in situ. IL-2 production by activated Jurkat T cells was decreased significantly when the cells were cocultured with IFN-
-pretreated uveal melanoma cells. IL-2 production was restored to over 70% by addition of either anti-PD-L1 or anti- PD-1 antibody into the coculture assays (P<0.01).
Conclusions: Expression of PD-L1 by uveal melanoma cells regulates T cell function by suppressing IL-2 production. This study implies that the presence of IFN-
in the tumor local microenvironment promotes upregulation of PD-L1 expression by uveal melanoma, which may, in part, promote immune escape by impairing T cell function. The selective blockade of PD-L1 is a potential strategy in T cell-based immunotherapy of uveal melanomas.
Key Words: melanoma, immunoregulation, immune privilege, cytokine
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |